VOX VIEW22 Apr 2021 10:40
At this stage of the Group’s development, and given the strong balance sheet, the key performance indicator for investors is now non-financial and based around the progression of the Affimer® and pre|CISION™ technologies progressing into clinical trials.
Healthcare services providers and governments are likely to be the largest volume customers of a professional use rapid antigen test and with an estimated price point in the mid-single digit GBP range. A higher price point is anticipated for sales to corporates for workforce testing.
With the Company and its industry partners estimated to be building capacity for between 5-30 million units per month, the upside in terms of revenue generation and subsequent valuation inflection points are clear.
Shares in AVCT have retreated from all time hights of 274p to open at 242p following the release of the FY20 results. However, with significant positive newsflow expected this year and significant revenue generation, the next 12 months are expected to be particularly strong for the shares.